We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biodegradable Stents in Lung Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00929942
Recruitment Status : Completed
First Posted : June 30, 2009
Last Update Posted : July 22, 2011
Sponsor:
Collaborator:
ELLA-CS, Czech Republic
Information provided by:
Hannover Medical School

Brief Summary:
A prospective observational trial involving 10 patients is planned. Intervention "SX-ELLA Stent Degradable DV Bronchial (DV Stent)" will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.

Condition or disease Intervention/treatment Phase
Lung Transplantation Device: SX-ELLA Stent Degradable DV Bronchial (DV Stent) Phase 1

Detailed Description:

Obstructive airway complications (OAC) (bronchial stenosis) are a significant problem in lung transplantation (LTx), and a special subset of chronic graft dysfunction. The overall rate is approximately 20% per recipient. Even though disobliteration (laser, argon-coagulation, cryotherapy) or balloon dilatation (bronchoplasty) are performed there is a high rate of recurrence. Self expandable metallic stents (SEMS) is one suggested treatment option after failed initial therapy but have a high rate of re-stenosis (50-60%). Morbidity, the risk for e.g. infection and atelectasis and lower long-term survival are often consequences in pts. treated with SEMS. No surgical options aside from re-do-transplantation are available. OAC are developing mostly in the time 3 - 6 months post Tx. The idea is a permanent but temporary therapy with replacement character of the stenosis which is given in degradable bronchial stents.

Hypothesis: New biodegradable bronchial stents are a successful treatment of benign bronchial stenosis after lung transplantation. After stent placement is further disobliteration is less frequently used during the next 6 months.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Benign Bronchial Airway Stenoses in Patients After Lung Transplantation With a Biodegradable Stent - a Proof of Concept Study
Study Start Date : June 2009
Primary Completion Date : April 2011
Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: DV Stent
Intervention "SX-ELLA Stent Degradable DV Bronchial (DV Stent)" will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.
Device: SX-ELLA Stent Degradable DV Bronchial (DV Stent)
Intervention "SX-ELLA Stent Degradable DV Bronchial (DV Stent)" will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.



Primary Outcome Measures :
  1. Show that DV stent can be safely placed in LTx recipients and are effective in relief of symptoms associated with OAC. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. To demonstrate mucosal healing in the first 6 months after stent insertion. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Recurrent airway complication (obstructive or necrotic) after single-order double-lung transplantation (at least twice balloon-dilatation or disobliteration therapy).
  • Patient at least 3 months after lung transplantation and followed in MHH outpatient clinic.
  • Target lesion in the left or right main stem bronchus, intermediate bronchus, right or left lower lobe, left upper lobe. Multiple lesions are eligible for inclusion and treatment but DV-stent implantation in different target lesions should be at least 6 weeks apart.

Exclusion Criteria:

  • Pregnant or breast feeding women.
  • Patients who are using no double-barrier method of birth control.
  • Previous use of a metallic stent (SEMS).
  • Target lesion in the middle lobe bronchus, right upper lobe, carina or trachea.
  • Previous use of brachytherapy or topical mitomycin.
  • Pats. after heart-lung transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00929942


Locations
Germany
Hannover Medical School
Hannover, Germany, 30625
Sponsors and Collaborators
Hannover Medical School
ELLA-CS, Czech Republic
Investigators
Principal Investigator: Jens T Gottlieb, M.D. Hannover Medical School

Responsible Party: Karel Volenec, ELLA-CS, s.r.o.
ClinicalTrials.gov Identifier: NCT00929942     History of Changes
Other Study ID Numbers: 5237
First Posted: June 30, 2009    Key Record Dates
Last Update Posted: July 22, 2011
Last Verified: June 2009

Keywords provided by Hannover Medical School:
lung transplantation
bronchial stenosis
biodegradable stent